Bristol-Myers Squibb BMY today announced plans for an approximately
$250 million expansion of its large-scale biologics manufacturing facility in
Devens, Massachusetts. The expansion will introduce biologics development and
clinical trial manufacturing capabilities to the site, while adding
approximately 350 employees to the Devens workforce over time.
“Biologics are increasingly important in the treatment of serious diseases and
are a growing part of our company's pipeline of potential new therapies,” said
Lou Schmukler, president, Global Manufacturing & Supply. “This initiative is
designed to accelerate the development of new biologics medicines through the
closer alignment of biologics research and development, and manufacturing.”
Bristol-Myers Squibb plans to construct two new buildings on its 89-acre
Devens campus. One will be dedicated to Process Development, a group that
designs processes for early production of investigational biologics medicines.
A second building will house Clinical Manufacturing, where investigational
medicines will be produced to support clinical trials. Both represent new
capabilities for Devens, a site that in its early years has focused solely on
large-scale, bulk biologics manufacturing.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in